Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18170495 | 1.00 | HTR3A (0.43) | HTR3ASLC18A3SIGMAR1HTR2AHTR2C | |
| SCHEMBL18170528 | 1.00 | HTR3A (0.43) | HTR3ASLC18A3SIGMAR1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL18865712 | 0.98 | HTR3A (0.42) | HTR3ASLC18A3SIGMAR1HTR2AHTR2C | |
| SCHEMBL21193137 | 0.89 | CHEK1 (0.43) | HTR2A | |
| SCHEMBL1586961 | 0.88 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR2CMKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL18866040 | 0.87 | CHEK1 (0.43) | HTR2A | |
| Hydrochloric Acid SCHEMBL28541350 | 0.86 | SLC18A3 (0.41) | SLC18A3SIGMAR1HTR2CMKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL3861509 | 0.86 | SLC18A3 (0.41) | SLC18A3SIGMAR1HTR2CMKNK1MKNK2 | |
| SCHEMBL16906233 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL18556076 | 0.82 | CHRNB4 (0.35) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108295073-A | Multi-fluorinated compounds are as bruton's tyrosine kinase inhibitor | 浙江导明医药科技有限公司 | 2018-07-20 | — | — | CN | claimed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3696181-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-10189841-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| CN-108884068-A | 1- cyano-pyrolidin derivative as DUB inhibitor | 特殊治疗有限公司 | 2018-11-23 | — | — | CN | disclosed |
| WO-2018011681-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-01-18 | — | — | WO | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| EP-2358202-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010077624-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010051245-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051245-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | HTR3A 1521/4885SLC18A3 3833/4885SIGMAR1 1950/4885 |
| US-10189841-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | HTR3A 1521/4885SLC18A3 3833/4885SIGMAR1 1950/4885 |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | PAFAH1B3, PAFAH1B2, FAAH2 | HTR3A 1424/4885SLC18A3 4597/4885SIGMAR1 428/4885 |
| US-20190315715-A1 | NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME | VNN1, DPYD, MVD | HTR3A 2158/4885SLC18A3 650/4885SIGMAR1 1447/4885 |
| US-10906888-B2 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | VNN1, DPYD, MVD | HTR3A 2052/4885SLC18A3 608/4885SIGMAR1 1503/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | HTR3A 1521/4885SLC18A3 3833/4885SIGMAR1 1950/4885 |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | PAFAH1B3, PAFAH1B2, PAF1 | HTR3A 2643/4885SLC18A3 4617/4885SIGMAR1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.